
BMT/Oncologist & Associate CMO @StephensonCC | Assoc Professor of Medicine @UofOklahoma I Alumni @MDAndersonnews @VCUMassey | #CORDS lab, posts = my opinions
Oklahoma City, OK
Joined February 2019
- Tweets2.4K
- Following945
- Followers1.5K
- Likes7.8K
Taha A, MD, MBA retweeted
Save the date, Oklahoma City! 📅 The ICE-T Congress is coming to OKC on January 30, 2027. Join us to explore what’s next in cellular therapy and share ideas for bringing these treatments to more patients. See you in OKC! #ICETCongress #CellularTherapy @Taha_CancerDoc @USMIRCNEWS @US_HMC @Larvol @oncodaily @OpenMedKate
Taha A, MD, MBA retweeted
Excited to serve as faculty at the #ICETCongress where I’ll be debating bispecific vs CART with @MediHumdani Especially looking forward to catching up with old friends and colleagues from @StephensonCC! Thanks to @Taha_CancerDoc and rest of the organizers for the invite!
📣 It’s official! Meet the 28 speakers, moderators, and panelists for the National ICE-T Congress in Oklahoma City on January 30, 2027.
Join us for live debates in myeloma, lymphoma, and myeloid disease. Swipe to meet the faculty. See you in OKC! 👇
#ICETCongress #CellularTherapy
@kczmj @Taha_CancerDoc @msalmanfaisal @Larvol @OpenMedKate @YLeyfman @zarabaloc @CancerNetwrk @oncodaily @US_HMC @USMIRCNEWS @Maho_VuMedi_Hem @VuMediHemOnc @CurrentOncology
Taha A, MD, MBA retweeted
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm ashpublications.org/blood/ar… | #BPDCN #endcancer @lane_andy @LuskinMarlise @ShaiShimony @NitinJainMD @Daver_Leukemia @mkonople @doctorpemm || @BloodPortfolio || @bcutd_research @VJHemOnc @TheIACH
Taha A, MD, MBA retweeted
#EHA2026 #AML #leusm
Dr. Barote: OPTI-AML: the first prospective RCT of Ven 14d vs 28d + Aza ×2 cycles in older AML — and it reframes the whole “shorter is fine” debate.
AV14 did NOT meet non-inferiority for CR (43% vs 49% AV28; ΔCI –8% to +21%, upper bound >10%).
Key takeaways 👇🏽
But the real story is molecular, not calendar:
• NPM1 & IDH1/2 → favored 28d (61% vs 42%)
• Every other subset → 44% vs 44%, identical
And cumulative delivery, not the planned schedule, tracked with response: pts who couldn’t complete Ven had lower CR in BOTH arms (AV28 39% vs 56%; AV14 36% vs 49%). Only 68% of AV28 finished C1 Ven (vs 89%) — mostly infections.
MRD negativity (78% vs 77%) and toxicity were superimposable. OS numerically favored AV28 but on MVA was driven by TP53/KRAS + counts, not arm.
Bottom line: Ven duration should be titrated to molecular subtype + triplet partner — what matters is cumulative exposure delivered, and for NPM1/IDH that exposure still earns its keep. #EHA2026 #EHA26
Taha A, MD, MBA retweeted
Replying to @OncBrothers @BijoyTelivala @RenoHemonc @PTarantinoMD @NVijayvergiaMD @ErikaHamilton9 @CathyEngMD @hoperugo @Dr_RShatsky @NiuSanford @GIMedOnc
OpenEvidence the GOAT. Still making some errors but it is getting better exponentially. No need for knowledge experts in future if you know what questions to ask. Good clinical skills and judgement will be needed not brut medical knowledge.
Taha A, MD, MBA retweeted
Late outcomes after posttransplant cyclophosphamide–based GVHD prophylaxis in patients with AML: an ALWP-EBMT study @BloodPortfolio @Bloodneoplasia
Taha A, MD, MBA retweeted
We have one of the best HemOnc fellowship programs in the nation at @StephensonCC, and the most supportive leaders! It’s a privilege to be here ✨
#ThankAResidentDay
Taha A, MD, MBA retweeted
Really excited about these updates to ChiefBrief
This Post is from an account that no longer exists. Learn more
Taha A, MD, MBA retweeted
New @CellCellPress
The hallmarks of cancer, refined from the original concepts 25 years ago, as an outgrowth of our expanding knowledge base
cell.com/cell/fulltext/S0092…
Taha A, MD, MBA retweeted
Insightful retrospective analysis published in @BrJHaem from @ChenyuLinMD et al. from @DukeHealth suggests no clear benefit of prophylactic dexamethasone in axi-cel recipients.
Following implementation at DUHS, there were no differences in the incidence, timing, duration, or severity of CRS or ICANS, nor in length of hospitalization, ICU utilization, or overall steroid exposure.
These findings persisted after multivariable adjustment.
Do you give prophy dex at your center? (we rarely do).
doi.org/10.1111/bjh.70343Dig…
Taha A, MD, MBA retweeted
My favorite interview so far: #nickrichardson, former FDA Dep Director for Heme Malig, about MRD from regulatory standpoint.
What will it take for other fields to turn MRD into endpoint for accel approval the way we've thankfully done in myeloma #MMsm?
I learned a lot here!
#MRD has rapidly moved to a focus of clinical trial design in hematologic malignancies. @RahulBanerjeeMD and Nicholas Richardson @Precision4Med sat down to talk about MRD assays, regulatory status, and the #FDA ODAC on MRD in multiple myeloma.
Watch here! youtu.be/1x-Pu5DWQCc
Taha A, MD, MBA retweeted
Yes
3/4 of these AML patients had high risk disease, in which past observational studies have shown CR rates of only 20-40% with traditional 7+3
With PARADIGM, we see higher response rates, and superior, statistically significant event-free survival with a plateau, favoring venetoclax/HMA over 7+3
“Tossing out” is too strong a phrase, but I would say prudent refinement with more targeted venetoclax-based approaches in high risk AML, reserving 7+3 backbone in the following subtypes:
NPM1
CBF
FLT3
MLL
RAD
monoblastic disease
Since the end goal for these fit, high risk individuals has to be allo transplant, patients getting venetoclax/HMA were more likely to be bridged accordingly than those who received 7+3 (61% vs 40%)
#ASH25
I’m not a leukemia AML doc. So Im struggling to understand this.
The PARADIGM study is a randomized phase II, not phase III. Are these results with Aza/Ven vs 7+3 sufficient to be considered paradigm changing to toss out decades of practice? What am I missing? What are the caveats for community practice? #ASH25
@DrHKantarjian @sanamloghavi @MikkaelSekeres @beatalleukemia
Taha A, MD, MBA retweeted
The VERONA study results are out!
In intermediate and high risk MDS, the addition of venetoclax to hypomethylating agent therapy enhances response rates but DOES NOT IMPROVE SURVIVAL
However, patients who got randomized to venetoclax were more likely to be transplanted
It’s possible venetoclax does improve overall survival in MDS patients, provided that the drug is used as a bridge to a potentially curative allogeneic stem cell transplant. However, that subgroup analysis is still yet to be conducted. Hopefully, we know at #ASH26
#ASH25 @aamdsif
Taha A, MD, MBA retweeted
My favorite is the IL18 cytokine as your armor for battle, huh. @ASH_hematology @ASCO @EHA_Hematology @ILROGTeam @MDAndersonNews
Taha A, MD, MBA retweeted
I’m not a leukemia AML doc. So Im struggling to understand this.
The PARADIGM study is a randomized phase II, not phase III. Are these results with Aza/Ven vs 7+3 sufficient to be considered paradigm changing to toss out decades of practice? What am I missing? What are the caveats for community practice? #ASH25
@DrHKantarjian @sanamloghavi @MikkaelSekeres @beatalleukemia
Taha A, MD, MBA retweeted
Huge congratulations to Amir Fathi for delivering one of the most impactful plenary presentations @ASH_hematology in AML in past decade. The PARADIGM study may lead to a Paradigm shift- Aza/Ven > intensive chemo in newly Dx high-risk AML. 👏👏👏
Taha A, MD, MBA retweeted
Three trials I wish we could see in the myeloma world — but sadly, they’re unlikely to happen 😔🩸
1️⃣ RCT in NDMM comparing Isatuximab vs Daratumumab in quadruplet regimens for both transplant-eligible & ineligible patients 🔬
2️⃣ RCT comparing Cilta-Cel vs Anito-Cel — not for efficacy, but to see which has lower toxicity 🧪⚠️
3️⃣ RCT of combo therapies: Teclistamab vs Elranatamab vs Linvoseltamab (paired with a anti-myeloma agent, preferably Daratumumab) to compare side-effects & patient satisfaction 💊🙂
#ASH25 #USMIRC #mmsm #myeloma #MedEd @USMIRCNEWS @US_HMC @ASH_hematology @Larvol @MedwatchKate @OncoAlert












































